EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Monoclonal Antibodies in Relapsed-Refractory Multiple Myeloma

Ilaria Sorgiovanni, Maria Livia Del Giudice iD, Sara Galimberti, Gabriele Buda

Pharmaceuticals · 22.01.2025 · 18 (2) · 145

DOI: 10.3390/ph18020145 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 22.01.2025. Verfasst von Ilaria Sorgiovanni und 3 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Division, University of Pisa, via Roma, 67, 56126 Pisa, Italy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multiple myeloma is a malignant hematological tumor characterized by the proliferation of clonal plasma cells in the bone marrow causing organ damage. Despite improved survival rates due to the increasing availability of therapeutic options in recent decades, it remains an incurable disease, with most patients ultimately relapsing. Consequently, relapsed/refractory multiple myeloma disease (RRMM) has become a treatment priority. Immunotherapy is the backbone of treatment in RRMM, starting with monoclonal antibodies such as elotuzumab, daratumumab, and isatuximab. The aim of this review is summarizing the results of RRMM trials with monoclonal antibodies and of the principal ongoing trials containing them. Additionally, we put a brief focus on novel drugs (such as bispecific antibodies) to provide a better overview. The advent of monoclonal antibodies has been nothing short of a game-changer for multi-refractory patients. It has opened up a whole new world of possibilities, offering myeloma patients a brighter and more hopeful future, even in the face of relapse.

Schlagwörter

Stichwörter der Autor:innen

immunotherapymonoclonal antibodiesmultiple myeloma

Autor:innen und Institutionen

  • Hematology Division, University of Pisa, via Roma, 67, 56126 Pisa, Italy.

ORCID-Profile: Maria Livia Del Giudice

Zitieren

APA

Sorgiovanni, I., Del Giudice, M. L., Galimberti, S., & Buda, G. (2025). Monoclonal Antibodies in Relapsed-Refractory Multiple Myeloma. Pharmaceuticals, 18(2), 145. https://doi.org/10.3390/ph18020145

Vancouver

Sorgiovanni I, Del Giudice ML, Galimberti S, Buda G. Monoclonal Antibodies in Relapsed-Refractory Multiple Myeloma. Pharmaceuticals. 2025;18(2):145. doi:10.3390/ph18020145

BibTeX
@article{Sorgiovanni2025,
  author = {Sorgiovanni, Ilaria and Del Giudice, Maria Livia and Galimberti, Sara and Buda, Gabriele},
  title = {Monoclonal Antibodies in Relapsed-Refractory Multiple Myeloma},
  journal = {Pharmaceuticals},
  year = {2025},
  volume = {18},
  number = {2},
  pages = {145},
  doi = {10.3390/ph18020145}
}
Kostenlos starten →